It doesn't get more global than Dentons, whose decentralised structure covers over 60 jurisdictions worldwide.
Please click here to view the full release.
To view the full release click here. Arecor presenting at the Bioprocessing Summit, Boston, MA Arecor Ltd, the UK-based leading formulation technology company, focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, is pleased to announce its participation at the Bioprocessing Summit, 13thth Augustat the Sheraton Boston Hotel, Boston, Massachusetts, USA.
The Bioprocessing Summit convenes more than 1, international bioprocess professionals to share practical solutions for today's bioprocessing challenges. Now in its tenth year, the event has grown to include 17 distinct conferences with weeklong programming on upstream and downstream processing, analytical development and quality, formulation and stability, cell and gene therapy production, and manufacturing.
Along with the impressive array of conferences, the Summit also includes short courses and training seminars that provide in-depth coverage of critical bioprocess topics.
For more information about the summit, please visit http: Thursday 16th, 6pm-9pm Short course: Having attended this conference several times in the past, I know that it is an excellent forum to learn about the latest advances in biopharmaceutical development and have a number of very interesting discussions with a wide range of interesting people.
Arecor keeps making great strides in developing highly differentiated biopharmaceutical products through application or our proprietary formulation technology. In order to succeed it is critical for us to keep up-to-date with the latest developments in the industry as well as receiving a constructive feedback on our technology and product strategy.
The Bioprocessing Summit is an excellent event to achieve that. NodThera was created and seed funded by life science investor, Epidarex Capital in based on earlier research conducted at Selvita, a Polish drug discovery company which remains a shareholder in NodThera.
We believe this approach has the potential to transform the treatment of patients suffering from these diseases where there are limited or no treatment options available.
NodThera is committed to discovering and developing first-in-class molecules in our core disease areas, and working with the best partners in this space to address other chronic inflammation driven therapeutic areas.
Together with our highly experienced management team, a strong scientific advisory board and the support of our international blue-chip investors, we are fully equipped to achieve our future goals.
The NodThera strategy is to develop its leading drug candidate through to proof-of-concept in humans in an inflammatory disease and to bring forward further drug candidates specifically addressing high unmet medical needs such as neurodegenerative diseases and certain cancers.
Next generation ready-to-use co-formulations of biotherapeutics: Alan Dickson, at the Manchester Institute of Biotechnology, commented: A combination of the high therapeutic dose and the highly desirable low injection volume often leads to a need for very highly concentrated formulations of protein based therapeutics.
Achieving such concentrated formulations can be exceptionally challenging. Arecor has developed a novel proprietary technology to formulating highly concentrated compositions of therapeutic proteins with low viscosity and a very low rate of aggregation, thus enabling a subcutaneous delivery of high value products where other approaches have failed.
The technology consists of several novel formulation platforms and computational algorithms that identify unique combinations of excipients to achieve the required stability and viscosity for any given protein.
We have been very successful in patenting unique combinations of excipients that impart considerably improved stability of protein and peptide-based therapeutics, as well as different types of vaccines. This new patent relates specifically to concentrated protein formulations, which is one of the most challenging and fastest growing areas of the biopharmaceutical industry.
The patent considerably strengthens our patent portfolio and our position as a world leader in the formulation of superior biotherapeutics and vaccines.
The product, which is scheduled to progress into a first-in-human clinical study in people with type 1 diabetes inis a significant step toward enabling miniaturization of next-generation insulin delivery technologies that are promising to transform the life of people with diabetes.About us techUK represents the companies and technologies that are defining today the world that we will live in tomorrow.
More than companies are members of techUK. Collectively they employ approximately , people, about half of all tech sector jobs in the UK. What Is the Watson Glaser Test? The Watson Glaser Critical Thinking Appraisal (WGCTA) is a verbal-style test produced by Pearson TalentLens in the UK.
It is administered by employers as either as an online test (usually unsupervised at home, or in some cases at a Pearson Vue test centre), or as a paper-based test in an assessment centre.
Evidence shows organisations that take steps to close their gender pay gap are more productive, more innovative, and more profitable.
Closing your pay gap won’t happen on its own, or overnight, and like any other business issue it requires a strategic and systematic approach.
If you are planning on working at the international law firm Hogan Lovells, you should know that the application process includes sitting the Watson-Glaser Critical Thinking Test. Hogan Lovells’ graduate careers section online includes a sample practice session of Watson-Glaser questions.
While answers to questions are available, there are no tips or extra practice questions [ ]. The following organisations have received Cyber Essentials certificates through CREST.
CREST is an approved accreditation body under the UK Government Cyber Essentials scheme. Further information about the role of CREST can be found at attheheels.com. Please note that CREST operates alongside other UK Government approved Accreditation Bodies.
With so many paths to choose from in the law, Hogan Lovells provides an excellent antidote to FOMO: a list of seats as long as your arm, and recognised quality in pretty much every team with an available spot.